238 related articles for article (PubMed ID: 29729689)
21. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
22. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
23. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
24. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
[TBL] [Abstract][Full Text] [Related]
25. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
26. Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.
Fadare O; Renshaw IL; Liang SX
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):352-9. PubMed ID: 21285872
[TBL] [Abstract][Full Text] [Related]
27. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
[TBL] [Abstract][Full Text] [Related]
28. Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
Comunoğlu NU; Durak H; Comunoğlu C; Ekici AI; Ozkan F; Akyildiz EU; Ilvan S; Calay Z; Molinas N
APMIS; 2007 Jun; 115(6):726-35. PubMed ID: 17550381
[TBL] [Abstract][Full Text] [Related]
29. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
[TBL] [Abstract][Full Text] [Related]
30. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
Esposito NN; Hunt JL; Bakker A; Jones MW
Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
32. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
[TBL] [Abstract][Full Text] [Related]
33. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
Liang Y; Zhang X; Chen X; Lü W
Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
[TBL] [Abstract][Full Text] [Related]
35. CD56 is Expressed in Uterine Smooth Muscle Tumors.
Karpathiou G; Chauleur C; Papoudou-Bai A; Dagher S; Peoc'h M
Int J Gynecol Pathol; 2021 Jul; 40(4):315-323. PubMed ID: 32897962
[TBL] [Abstract][Full Text] [Related]
36. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Müllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases.
Patil DT; Laskin WB; Fetsch JF; Miettinen M
Am J Surg Pathol; 2011 Mar; 35(3):315-24. PubMed ID: 21297441
[TBL] [Abstract][Full Text] [Related]
37. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
[TBL] [Abstract][Full Text] [Related]
38. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor.
Watanabe K; Kusakabe T; Hoshi N; Saito A; Suzuki T
Hum Pathol; 1999 Apr; 30(4):392-6. PubMed ID: 10208459
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice.
Moore AB; He H; Yoshida A; Rico PJ; Haseman JK; Dixon D
Exp Toxicol Pathol; 2000 Jun; 52(3):195-200. PubMed ID: 10930119
[TBL] [Abstract][Full Text] [Related]
40. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]